AngioDynamics revenue jumps 9.1% as hospital staff shortages continue to impact sales

The Latham manufacturer is in the midst of a multiyear shift away from lower-margin legacy products as CEO Jim Clemmer has refocused the business around the development higher-margin technology to combat blood clots and tumors.